Interethnic differences in the distribution of clinically relevant vascular endothelial growth factor genetic polymorphisms

DNA and Cell Biology

Volumn 28, Issue 11, 2009, Pages 567-572

  Muniz, Jaqueline J ^a   Izidoro Toledo, Tatiane C ^b   Metzger, Ingrid F ^b   Sandrim, Valeria C ^b   Tanus Santos, Jose E ^b  

^a UNIVERSITY OF CAMPINAS   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

VASCULOTROPIN;

ADULT; ALLELE; ARTICLE; CONTROLLED STUDY; ETHNIC DIFFERENCE; GENE FREQUENCY; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; LINKAGE ANALYSIS; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

ADOLESCENT; ADULT; AFRICAN CONTINENTAL ANCESTRY GROUP; BRAZIL; CARDIOVASCULAR DISEASES; EUROPEAN CONTINENTAL ANCESTRY GROUP; HAPLOTYPES; HUMANS; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; YOUNG ADULT;

EID: 70350452566     PISSN: 10445498     EISSN: None     Source Type: Journal    
DOI: 10.1089/dna.2009.0925     Document Type: Article

References (42)

1. Akiri, G., Nahari, D., Finkelstein, Y., Le, S.Y., Elroy-Stein, O., and Levi, B.Z. (1998) Regulation of vascular endothelial growth factor (VEGF) expression is mediated by internal initiation of translation and alternative initiation of transcription. Oncogene 17, 227-236.
2. Awata, T., Inoue, K., Kurihara, S., Ohkubo, T., Watanabe, M., Inukai, K., Inoue, I., and Katayama, S. (2002) A common polymorphism in the 50-untranslated region of the VEGF gene is associated with diabetic retinopathy in type 2 diabetes. Diabetes 51, 1635-1639.
3. Barbosa, F., Jr., Sandrim, V.C., Uzuelli, J.A., Gerlach, R.F., and Tanus-Santos, J.E. (2006) eNOS genotype-dependent correlation between whole blood lead and plasma nitric oxide products concentrations. Nitric Oxide 14, 58-64.
4. Biselli, P.M., Guerzoni, A.R., de Godoy, M.F., Pavarino-Bertelli, E.C., and Goloni-Bertollo, E.M. (2008) Vascular endothelial growth factor genetic variability and coronary artery disease in Brazilian population. Heart Vessels 23, 371-375.
5. Brogan, I.J., Khan, N., Isaac, K., Hutchinson, J.A., Pravica, V., and Hutchinson, I.V. (1999) Novel polymorphisms in the promoter and 50 UTR regions of the human vascular endothelial growth factor gene. Hum Immunol 60, 1245-1249.
6. Cardon, L.R., and Bell, J.I. (2001) Association study designs for complex diseases. Nat Rev Genet 2, 91-99.
7. Collins, F.S. (2004) What we do and don't know about ''race,'' ''ethnicity,'' genetics and health at the dawn of the genome era. Nat Genet 36, S13-S15.
8. Del Bo, R., Scarlato, M., Ghezzi, S., Maestroni, A., Sjolind, L., Forsblom, C., Wessman, M., Groop, P.H., Comi, G.P., Bresolin, N., Luzi, L., and Zerbini, G. (2006) VEGF gene variability and type 1 diabetes: evidence for a protective role. Immunogenetics 58, 107-112.
9. Douvaras, P., Antonatos, D.G., Kekou, K., Patsilinakos, S., Chouliaras, G., Christou, A., Andrikou, A., and Kanavakis, E. (2009) Association of VEGF gene polymorphisms with the development of heart failure in patients after myocardial infarction. Cardiology 114, 11-18.
10. Ferrante, M., Pierik, M., Henckaerts, L., Joossens, M., Claes, K., Van Schuerbeek, N., Vlietinck, R., Rutgeerts, P., Van Assche, G., and Vermeire, S. (2006) The role of vascular endothelial growth factor (VEGF) in inflammatory bowel disease. In- flamm Bowel Dis 12, 870-878.
11. Ferrara, N., Gerber, H.P., and LeCouter, J. (2003) The biology of VEGF and its receptors. Nat Med 9, 669-676.
12. Freathy, R.M., Weedon, M.N., Shields, B., Hitman, G.A., Walker, M., McCarthy, M.I., Hattersley, A.T., and Frayling, T.M. (2006) Functional variation in VEGF is not associated with type 2 diabetes in a United Kingdom Caucasian population. JOP 7, 295-302.
13. Girnita, D.M., Webber, S.A., Ferrell, R., Burckart, G.J., Brooks, M.M., McDade, K.K., Chinnock, R., Canter, C., Addonizio, L., Bernstein, D., Kirklin, J.K., Girnita, A.L., and Zeevi, A. (2006) Disparate distribution of 16 candidate single nucleotide polymorphisms among racial and ethnic groups of pediatric heart transplant patients. Transplantation 82, 1774-1780.
14. He, H., Venema, V.J., Gu, X., Venema, R.C., Marrero, M.B., and Caldwell, R.B. (1999) Vascular endothelial growth factor signals endothelial cell production of nitric oxide and prostacyclin through flk-1=KDR activation of c-Src. J Biol Chem 274, 25130-25135.
15. Howell, W.M., Ali, S., Rose-Zerilli, M.J., and Ye, S. (2005) VEGF polymorphisms and severity of atherosclerosis. J Med Genet 42, 485-490.
16. Huez, I., Bornes, S., Bresson, D., Creancier, L., and Prats, H. (2001) New vascular endothelial growth factor isoform generated by internal ribosome entry site-driven CUG translation initiation. Mol Endocrinol 15, 2197-2210.
17. Huez, I., Creancier, L., Audigier, S., Gensac, M.C., Prats, A.C., and Prats, H. (1998) Two independent internal ribosome entry sites are involved in translation initiation of vascular endothelial growth factor mRNA. Mol Cell Biol 18, 6178-6190.
18. Hutchings, H., Ortega, N., and Plouet, J. (2003) Extracellular matrix-bound vascular endothelial growth factor promotes endothelial cell adhesion, migration, and survival through integrin ligation. FASEB J 17, 1520-1522.
19. Kangas-Kontio, T., Tapanainen, J.M., Huikuri, H., Savolainen, E.R., Paivansalo, M., Kauma, H., Kesaniemi, Y.A., Savolainen, M.J., and Kakko, S. (2009) Variation in the vascular endothelial growth factor gene, carotid intima-media thickness and the risk of acute myocardial infarction. Scand J Clin Lab Invest 69, 335-343.
20. Kaufman, J.S. (1999) How inconsistencies in racial classification demystify the race construct in public health statistics. Epidemiology 10, 101-103.
21. Lambrechts, D., Storkebaum, E., Morimoto, M., Del-Favero, J., Desmet, F., Marklund, S.L., Wyns, S., Thijs, V., Andersson, J., van Marion, I., Al-Chalabi, A., Bornes, S., Musson, R., Hansen, V., Beckman, L., Adolfsson, R., Pall, H.S., Prats, H., Vermeire, S., Rutgeerts, P., Katayama, S., Awata, T., Leigh, N., Lang- Lazdunski, L., Dewerchin, M., Shaw, C., Moons, L., Vlietinck, R., Morrison, K.E., Robberecht, W., Van Broeckhoven, C., Collen, D., Andersen, P.M., and Carmeliet, P. (2003) VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death. Nat Genet 34, 383-394.
22. Luizon, M.R., Izidoro-Toledo, T.C., Simoes, A.L., and Tanus- Santos, J.E. (2009) Endothelial nitric oxide synthase polymorphisms and haplotypes in amerindians. DNA Cell Biol 28, 329-334.
23. Marroni, A.S., Metzger, I.F., Souza-Costa, D.C., Nagassaki, S., Sandrim, V.C., Correa, R.X., Rios-Santos, F., and Tanus- Santos, J.E. (2005) Consistent interethnic differences in the distribution of clinically relevant endothelial nitric oxide synthase (eNOS) genetic polymorphisms. Nitric Oxide 12, 177-182.
24. Parra, F.C., Amado, R.C., Lambertucci, J.R., Rocha, J., Antunes, C.M., and Pena, S.D. (2003) Color and genomic ancestry in Brazilians. Proc Natl Acad Sci USA 100, 177-182.
25. Petrovic, D., Verhovec, R., Globocnik Petrovic, M., Osredkar, J., and Peterlin, B. (2007) Association of vascular endothelial growth factor gene polymorphism with myocardial infarction in patients with type 2 diabetes. Cardiology 107, 291-295.
26. Prior, S.J., Hagberg, J.M., Paton, C.M., Douglass, L.W., Brown, M.D., McLenithan, J.C., and Roth, S.M. (2006) DNA sequence variation in the promoter region of the VEGF gene impacts VEGF gene expression and maximal oxygen consumption. Am J Physiol Heart Circ Physiol 290, H1848-H1855.
27. Pugh, C.W., and Ratcliffe, P.J. (2003) Regulation of angiogenesis by hypoxia: Role of the HIF system. Nat Med 9, 677-684.
28. Race, Ethnicity, and Genetics Working Group. (2005) The use of racial, ethnic, and ancestral categories in human genetics research. Am J Hum Genet 77, 519-532.
29. Rezende, V.B., Barbosa, F., Jr., Montenegro, M.F., Sandrim, V.C., Gerlach, R.F., and Tanus-Santos, J.E. (2007) An interethnic comparison of the distribution of vitamin D receptor genotypes and haplotypes. Clin Chim Acta 384, 155-159.
30. Rezende, V.B., Barbosa, F., Jr., Montenegro, M.F., Sandrim, V.C., Gerlach, R.F., and Tanus-Santos, J.E. (2008) Haplotypes of vitamin D receptor modulate the circulating levels of lead in exposed subjects. Arch Toxicol 82, 29-36.
31. Robinson, C.J., and Stringer, S.E. (2001) The splice variants of vascular endothelial growth factor (VEGF) and their receptors. J Cell Sci 114, 853-865.
32. Sandhofer, A., Tatarczyk, T., Kirchmair, R., Iglseder, B., Paulweber, B., Patsch, J.R., and Schratzberger, P. (2009) Are plasma VEGF and its soluble receptor sFlt-1 atherogenic risk factors? Cross-sectional data from the SAPHIR study. Atherosclerosis doi:10.1016=j.atherosclerosis.2009.01.031.
33. Sandrim, V.C., Coelho, E.B., Nobre, F., Arado, G.M., Lanchote, V.L., and Tanus-Santos, J.E. (2006a) Susceptible and protective eNOS haplotypes in hypertensive black and white subjects. Atherosclerosis 186, 428-432.
34. Sandrim, V.C., de Syllos, R.W., Lisboa, H.R., Tres, G.S., and Tanus-Santos, J.E. (2007) Influence of eNOS haplotypes on the plasma nitric oxide products concentrations in hypertensive and type 2 diabetes mellitus patients. Nitric Oxide 16, 348-355.
35. Sandrim, V.C., de Syllos, R.W.C., Lisboa, H.R., Tres, G.S., and Tanus-Santos, J.E. (2006b) Endothelial nitric oxide synthase haplotypes affect the susceptibility to hypertension in patients with type 2 diabetes mellitus. Atherosclerosis 189, 241-246.
36. Sandrim, V.C., Palei, A.C., Cavalli, R.C., Araujo, F.M., Ramos, E.S., Duarte, G., and Tanus-Santos, J.E. (2008) eNOS haplotypes associated with gestational hypertension or preeclampsia. Pharmacogenomics 9, 1467-1473.
37. Sandrim, V.C., Palei, A.C., Cavalli, R.C., Araujo, F.M., Ramos, E.S., Duarte, G., and Tanus-Santos, J.E. (2009) Vascular endothelial growth factor genotypes and haplotypes are associated with pre-eclampsia but not with gestational hypertension. Mol Hum Reprod 15, 115-120.
38. Sandrim, V.C., Yugar-Toledo, J.C., Desta, Z., Flockhart, D.A., Moreno H., Jr., and Tanus-Santos, J.E. (2006c) Endothelial nitric oxide synthase haplotypes are related to blood pressure elevation, but not to resistance to antihypertensive drug therapy. J Hypertens 24, 2393-2397.
39. Stein, I., Itin, A., Einat, P., Skaliter, R., Grossman, Z., and Keshet, E. (1998) Translation of vascular endothelial growth factor mRNA by internal ribosome entry: implications for translation under hypoxia. Mol Cell Biol 18, 3112-3119.
40. Tanus-Santos, J.E., Desai, M., and Flockhart, D.A. (2001) Effects of ethnicity on the distribution of clinically relevant endothelial nitric oxide variants. Pharmacogenetics 11, 719-725.
41. Yla-Herttuala, S., Rissanen, T.T., Vajanto, I., and Hartikainen, J. (2007) Vascular endothelial growth factors: biology and current status of clinical applications in cardiovascular medicine. J Am Coll Cardiol 49, 1015-1026.
42. Zachary, I. (2001) Signaling mechanisms mediating vascular protective actions of vascular endothelial growth factor. Am J Physiol Cell Physiol 280, C1375-C1386. (Pubitemid 32553192)